Inhibition of JAK kinases has been shown to disrupt IL-15 signaling, reduce TRM cell activity, and alleviate tissue damage in autoimmune conditions, supporting the therapeutic potential of JAK inhibitors in treating diseases like vitiligo. This evidence concerns the gene IL15 and vitiligo.